Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Cash-Flows-Other-Operating" stands at 5.20 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2013.
Johnson & Johnson's third quarter result of 2.22 Billion USD for the item "Cash Flows Other Operating" represents an increase of 168.85 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 2.22 Billion USD for the item "Cash Flows Other Operating" represents an increase of 2,364.44 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 5.20 Billion USD for the item "Cash Flows Other Operating" represents an increase of 69.29 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 9.78 Billion United States Dollars compared to the value the year prior.
The 1 year change is 9.78 Billion United States Dollars.
The 3 year change is 7.20 Billion United States Dollars.
The 5 year change is 5.79 Billion United States Dollars.
The 10 year change is 4.82 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Cash Flows Other Operating | 905,699,262,464.00 |
![]() | AbbVie Inc - Cash Flows Other Operating | 399,570,305,024.00 |
![]() | Roche Holding AG - Cash Flows Other Operating | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Cash Flows Other Operating | 280,205,508,085.11 |
![]() | Novartis AG - Cash Flows Other Operating | 255,096,620,580.91 |